

CURRICULUM VITAE**INFORMAZIONI
PERSONALI**

Nome	Giampiero Girolomoni
Qualifica	Professore ordinario e Direttore Sezione Dermatologia e Venereologia, Dipartimento di Medicina, Scuola di Medicina e Chirurgia, Università di Verona; Direttore della U.O.C. Dermatologia dell'Azienda Ospedaliera Universitaria Integrata di Verona

**TITOLI DI STUDIO E
PROFESSIONALI –
ESPERIENZE LAVORATIVE**

Titoli di studio	1976 Diploma di maturità classica – Liceo Mamiani, Pesaro 1983 Laurea in Medicina e Chirurgia – Università di Modena Iscritto Ordine dei Medici PU1622
Altri titoli di studio	1986 Specialista in Dermatologia e Venereologia– Università di Modena
Esperienze professionali (incarichi ricoperti)	1988–1990 Immunodermatology Fellow, Visiting Instructor, Dipart. di Dermatologia, University of Texas Southwestern Medical School, Dallas, TX, USA 1990–1994 Assistente Medico, Clinica Dermatologica, Università di Modena 1994–2004 Direttore Laboratorio di Ricerca di Immunologia; Primario Seconda Divisione di Dermatologia, Direttore Dipartimento di Dermatologia Clinica, Istituto Dermopatico dell'Immacolata, Roma 2005–2018 Direttore scuola di specializzazione in Dermatologia e Venereologia, Università di Verona
Capacità linguistiche	Ottima conoscenza scritta e parlata della lingua inglese
Premi e Onorificenze	1990 Outstanding Research Award: The Upjohn Company and the Department of Dermatology, UTSMC, Dallas, TX 1993 Scientific award: 2 nd Tricontinental Meeting JSID/SID/ESDR. Kyoto 2015 Pro–meritis Award: 2015 European Dermatology Forum, Bern 2016 Ehrenmitglied, Deutsche Dermatologische Gessellschaf 2017 Commendatore, Ordine al Merito della Repubblica Italiana, Presidenza del Consiglio dei Mministri 2017 Scientific Achievement Award, European Academy of Dermatology and Venereology, Geneva 2018 Marchigiano dell'Anno 2017. Centro Studi Marche “Giuseppe Giunchi” – Senato della Repubblica 2018 Membro corrispondente Società Svizzera di Dermatologia e Venereologia 2019 Presidente emerito Società Italiana di Dermatologia (Sidemast) 2020 Certificate of appreciation International League of Dermatological Societies
Attività Scientifiche	Fisiopatologia delle reazioni immunitarie cellulo–mediate della cute,

	<p>immunofarmacologia ed epidemiologia delle malattie infiammatorie croniche della cute. Dermatologia clinica: malattie cutanee nell'immunodepresso, reazioni cutanee da farmaci, manifestazioni cutanee delle malattie interne, complicanze cardio-metaboliche delle malattie infiammatorie croniche. Esperienze acquisite nel settore scientifico oggetto di sperimentazione secondo le norme di Buona Pratica Clinica (GCP), maturate nell'ambito di numerosi studi clinici nonché dell'assistenza ai pazienti. Principal investigator in oltre 150 trial clinici internazionali e nazionali. Past president European Dermatology Forum (EDF; 2011–2012) e Società Italiana di Dermatologia (Sidemast; 2014–2016). Editor della sezione Clinical Immunology di Vaccines. Associate Editor di Frontiers in Medicine (Dermatology). Membro del Comitato editorial di European Journal of Dermatology, the Journal of the German Society of Dermatology, the Journal of Dermatology, European Annals of Allergy and Clinical Immunology, e section editor di Vaccines. Presidente e/o responsabile scientifico di 155 congressi nazionali o internazionali. Letture a invito 1988–2021: 945.</p>
--	--

<p>Pubblicazioni Scientifiche</p>	<p>Co-autore di 415 articoli originali, 195 reviews, 89 capitoli di libri o monografie, 1110 abstracts per congressi, e co-autore o co-editore di 5 libri. IF globale >2700; IF medio = 4.54; Citazioni >30000; H-index: 92, i10 H-index: 358 (Scholar).</p>
--	--

PRINCIPALI PUBBLICAZIONI 2019–2021:

1. Gambichler T, Mahjuria-Namari M, Reininghaus L, Schmitz L, Skrygan M, Schulze HJ, Schaller J, Girolomoni G. Lysyl oxidase-like-2 mutations and reduced mRNA and protein expression in mid-dermal elastolysis. *Clin Exp Dermatol* 44:47–51, 2019.
2. Fassio I, Gatti D, Rossini M, Idolazzi L, Giollo A, Adami G, Gisondi P, Girolomoni G, Viapiana O. Secukinumab produces a quick increase in WNT signaling antagonists in patients with psoriatic arthritis. *Clin Exp Rheumatol* 37:133–136, 2019.
3. Gisondi P, Girolomoni G. The multifaceted association between psoriasis and obesity. *Br J Dermatol* 180:24, 2019.
4. Gisondi P, Bianchi L, Calzavara Pinton P, Conti A, Chiricozzi A, Fimiani M, Giunta A, Prignano F, Tiberio R, Venturini M, Girolomoni G. Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. *Br J Dermatol* 180:409–410, 2019.
5. Sampogna F, Puig L, Spuls P, Girolomoni G, Radtke MA, Kirby B, Brunori M, Bergmans P, Smirnov P, Rundle J, Castiglia A, Lavie F, Paul C. Reversibility of alexithymia with effective treatment of moderate to severe psoriasis: longitudinal data from EPIDEPSO. *Br J Dermatol* 180:397–403, 2019.
6. Chiricozzi A, Belloni Fortina A, Galli E, Girolomoni G, Neri I, Ricci G, Romanelli M, Peroni D. Current therapeutic paradigm in pediatric atopic dermatitis: practical guidance from a national expert panel. *Allergol Immunopathol (Madr)* 47:194–206, 2019.
7. Caletti C, Manuel Ferraro P, Corvo A, Tessari G, Sandrini S, Capelli I, Minetti E, Gesualdo L, Girolomoni G, Boschiero L, Lupo A, Zaza G. Impact of 3 major maintenance immunosuppressive protocols on long-term clinical outcomes: result of a large multicenter italian cohort study including 5635 renal transplant recipients. *Transplant Proc* 51:136–139, 2019.
8. Bellinato F, Maurelli M, Colato C, Balter R, Girolomoni G, Schena D. BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. *Br J Dermatol* 180:933–934, 2019.
9. Marzano AV, Genovese G, Casazza G, Fierro MT, Dapavo P, Crimi N, Ferrucci S, Pepe P, Liberati S, Pigatto PD, Offidani A, Martina E, Girolomoni G, Rovaris M, Foti C, Stingeni L, Cristaudo A, Canonica GW, Nettis E, Asero R. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. *J Eur Acad Dermatol Venereol* 33:918–924, 2019.
10. Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. *Expert Opin Pharmacother* 20:863–872, 2019.
11. Gisondi P, Pezzolo E, Girolomoni G. Glomerular filtration rate in patients with moderate-to-severe psoriasis. *J Eur Acad Dermatol Venereol* 33:e244–e245, 2019.
12. Gisondi P, Mattiucci A, Tonin B, Girolomoni G. Low dose acitretin versus methotrexate in the treatment of palmoplantar psoriasis: a case series. *J Eur Acad Dermatol Venereol* 33:e246–e247, 2019.

13. Gisondi P, Geat D, Pizzolato M, Girolomoni G. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. *Curr Opin Pharmacol* 46:90–99, 2019.
14. Madonna S, Girolomoni G, Dinarello CA, Albanesi C. The significance of IL–36 hyperactivation and IL–36R targeting in psoriasis. *Int J Mol Sci* 20:E3318, 2019.
15. Guicciardi F, Atzori L, Marzano AV, Tavecchio S, Girolomoni G, Colato C, Kanitakis J, Mitteldorf C, Satta R, Cribier B, Gusdorf L, Calzavara–Pinton P, Fernandez–Figueras M, Kempf W, Filosa G, Rongioletti F. Are there distinct clinical and pathological features distinguishing idiopathic from drug–induced subacute cutaneous lupus erythematosus? An European retrospective multicenter study. *J Am Acad Dermatol Venereol* 81:403–411, 2019.
16. Caletti C, Ferraro PM, Corvo A, Tessari G, Sandrini S, Capelli I, Minetti E, Gesualdo L, Girolomoni G, Boschiero L, Lupo A, Zaza G. Mantenimento del trapianto renale: impatto clinico a lungo termine di tre diversi protocolli immunosoppressivi Risultati di un ampio studio multicentrico italiano. *Trapianti* 1:17–21, 2019.
17. Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, Peris K, Potenza P, Offidani A, Bartezaghi M, Aloisi E, Costanzo A. Secukinumab shows high efficacy irrespective of HLA–Cw6 status in patients with moderate–to–severe plaque–type psoriasis: results from extension phase of the SUPREME study. *Br J Dermatol* 181:413–414, 2019.
18. Gisondi P, Geat D, Idolazzi L, Girolomoni G. Relapse of psoriatic arthritis in patients with active psoriasis switched from tumor necrosis factor– to interleukin–17A inhibitor. *Br J Dermatol* 181:624–626, 2019.
19. Maurelli M, Colato C, Girolomoni G. Palisaded neutrophilic granulomatous dermatitis and its associations with autoimmune diseases. *Eur J Dermatol* 29:432–433, 2019.
20. Bellinato F, Maurelli M, Gisondi P, Girolomoni G. A systematic review of treatments for pityriasis lichenoides. *J Eur Acad Dermatol Venereol* 33:2039–2049, 2019.
21. Di Lernia V, Bianchi L, Guerriero C, Stingeni L, Gisondi P, Filoni A, Guarneri C, Belloni Fortina A, Lasagni C, Simonetti O, Neri I, Zangrilli A, Moretta G, Hansel K, Casanova D, Girolomoni G, Cannavò SP, Bonamonte D. Adalimumab in severe plaque psoriasis of childhood: a multi–center, retrospective real–life study up to 52 weeks observation. *Dermatol Ther* 32:e13091, 2019.
22. Bellinato F, Gisondi P, Girolomoni G. Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission. *Br J Dermatol* 181:1319–1320, 2019.
23. Gisondi P, Rovaris M, Piaserico S, Girolomoni G. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. *Br J Dermatol* 182:175–179, 2020.
24. Fania L, Morelli M, Scarponi C, Mercurio L, Scopelliti F, Cattani G, Scaglione GL, Tonanzi T, Pilla MA, Pagnanelli G, Mazzanti C, Girolomoni G, Cavani A, Madonna S, Albanesi C. Paradoxical psoriasis induced by TNF– blockade shows immunological features typical of the early phase of psoriasis development. *J Pathol Clin Res* 6:55–68, 2020.
25. Patruno C, Amerio P, Chiricozzi A, Costanzo A, Cristuado A, Cusano F, Foti C, Girolomoni G, Guarneri F, Naldi L, Offidani A, Pigatto P, Prignano F, Stingeni L, Calzavara Pinton P. Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA). *G Ital Dermatol Venereol* 155:1–7, 2020.
26. Calzavara–Pinton P, Fabbrocini G, Girolomoni G, Matiucci A, Micali G, Musumeci ML, Patruno C, Pellacani G, Rossi MT, Stingeni L, Castello M. Topical tacrolimus in adult atopic dermatitis: a consensus based on a 15–year experience. *G It Dermatol Venereol* 155:8–13, 2020.
27. Sciattella P, Pellacani G, Pigatto PD, Patrizi A, Peris K, Calzavara Pinton P, Girolomoni G, Lanati EP, D’Ausilio A, Mennini FS. The burden of atopic dermatitis in adults in Italy. *G It Dermatol Venereol* 155:19–23, 2020.
28. Maurelli M, Gisondi P, Girolomoni G. Visual vignette. Metastatic glucagonoma. *Endocr Pract* 26:253, 2020.
29. Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio–metabolic comorbidities. *Front Pharmacol* 11:117, 2020.
30. Tonin B, Pizzolato M, Furci A, Girolomoni G. Cutaneous pili migrans. *Open J Clin Med Case Rep* 1635, 2020.
31. Vimercati L, De Maria L, Caputi A, Sabrina E, Cannone S, Mansi F, Cavone D, Romita P, Argenziano G, Di Stefani A, Parodi A, Peris K, Scalvenzi M, Girolomoni G, Foti C. Non–melanoma skin cancer in outdoor workers: a study on actinic keratosis in Italian navy personnel. *Int J Environ Res Public Health* 17:E2321, 2020.
32. Maurelli M, Bellinato F, Gisondi P, Girolomoni G. Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination. *Vaccine* 38:3808–3809, 2020.
33. Virgili A, Borghi A, Cazzaniga S, DI Landro A, Naldi L, Minghetti S, Fierro MT, Verrone A, Caproni M, Micali G, Gaspari V, Papini M, DI Lernia V, Germi L, Girolomoni G, Belloni Fortina A, Cannavò SP, Bilenchi R, Corazza M. Gender differences in genital lichen sclerosus: data from a multicenter Italian study on 729 consecutive cases. *G Ital Dermatol Venereol* 155:155–160, 2020.
34. de Bruin–Weller M, Gadkari A, Auziere S, Simpson EL, Puig L, Barbarot S, Girolomoni G, Papp K, Pink AE, Saba G, Werfel T, Eckert L. The patient–reported disease burden in adults with atopic dermatitis: a cross–sectional study in Europe

- and Canada. *J Eur Acad Dermatol Venereol* 34:1026–1036, 2020.
35. Maurelli M, Gisondi P, Danese E, Gelati M, Papagrigoraki A, del Giglio M, Lippi G, Girolomoni G. Psoriasin (S100A7) is increased in serum of patients with moderate to severe psoriasis. *Br J Dermatol* 182:1479–1506, 2020.
 36. Alexander H, Paller AS, Traidl-Hoffmann C, Beck LA, Debenedetto A, Dhar S, Girolomoni G, Irvine A, Spuls P, Su J, Thyssen J, Vestergaard C, Weinstein M, Werfel T, Wollenberg A, Deleuran M, Flohr C. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. *Br J Dermatol* 182:1331–1342, 2020.
 37. Bellinato F, Maurelli M, Colato C, Girolomoni G. Amicrobial pustulosis of the folds: report of three new cases. *Indian J Dermatol* 65:323–324, 2020.
 38. Chiricozzi A, Maurelli M, Gori N, Argenziano G, De Simone C, Calabrese G, Girolomoni G, Peris K. Dupilumab improves clinical manifestations, symptoms and quality of life in adult patients with chronic nodular prurigo. *J Am Acad Dermatol* 83:39–45, 2020.
 39. Egeberg A, Girolomoni G, Feldman SR, Radtke MA, Carrascosa JM, Ghil J, Keum JW, Lee J, Seo H. Real world SB4 (Etanercept Biosimilar) use in patients with psoriasis: data from the British Association of Dermatologists Biologic Interventions Register (BADBIR). *J Drugs Dermatol* 19:316–318, 2020.
 40. Hadaschik E, Eming R, French LE, Girolomoni G, Hertl M, Jolles S, Karpati S, Steinbrink K, Stingl G, Volc-Platzer B, Zillikens D, Enk A. Europäische Leitlinien (S1) für die Verwendung von hochdosierten intravenösen Immunglobulinen in der Dermatologie. *Hautarzt* 71:542–552, 2020.
 41. Tonin B, Geat D, Girolomoni G. Bleomycin-induced flagellate dermatitis: a case report. *Serbian Journal of Dermatology and Venereology* 12:21–24, 2020.
 42. Bellinato F, Gisondi P, Girolomoni G. A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. *Expert Rev Clin Pharmacol* 13:481–491, 2020.
 43. Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G. Psoriatic arthritis and diabetes mellitus: a narrative review. *Rheumatol Ther* 7:271–285, 2020.
 44. Gisondi P, Zaza, Del Giglio M, Rossi M, Iacono V, Girolomoni G. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment. *J Am Acad Dermatol* 83:285–287, 2020.
 45. Gisondi P, Geat D, Conti A, Dapavo P, Piaserico S, De Simone C, Bianchi L, Costanzo A, Malagoli P, Malara G, Micali G, Naldi L, Offidani M, Patrizi A, Prignano F, Parodi A, Rongioletti F, Calzarava-Pinton P, Girolomoni G. TNF- α inhibitors biosimilars as first line systemic treatment for moderate to severe chronic plaque psoriasis. *Expert Rev Clin Immunol* 16:591–598, 2020.
 46. Gisondi P, Virga C, Piaserico S, Meneguzzo A, Odorici G, Conti A, Girolomoni G. Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. *Br J Dermatol* 183:397–398, 2020.
 47. Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Clinical features and treatments of transient acantholytic dermatosis (Grover's disease): A systematic review. *J Dtsch Dermatol Ges* 18:826–833, 2020.
 48. Tonin B, Geat D, Girolomoni G. A case of kerion celsi caused by *Trichophyton tonsurans*. *Pediatr Int* 62:1007–1008, 2020.
 49. Gisondi P, Bellinato F, Conti A, Dapavo P, Piaserico S, De Simone C, Chiricozzi A, Dattola A, Malagoli P, Malara G, Campanati A, Burlando M, Esposito M, Girolomoni G. Consensus on the place in therapy of TNF- α inhibitors in the treatment of patients with chronic plaque psoriasis. *J Eur Acad Dermatol Venereol* 34:e470–e472, 2020.
 50. Tonin B, Colato C, Bruni M, Girolomoni G. Late granuloma formation secondary to hyaluronic acid injection. *Dermatol Online J* 2020;26:13030/qt9fj4f3ts.
 51. Pahar B, Madonna S, Das, Albanesi C, Girolomoni G. Immunomodulatory role of the antimicrobial LL-37 peptide in autoimmune diseases and viral infections. *Vaccines (Basel)* 8:E517, 2020.
 52. Chiricozzi A, Maurelli M, Peris K, Girolomoni G. Targeting IL-4 for the treatment of atopic dermatitis. *Immunotargets Ther* 9:151–156, 2020.
 53. Gisondi P, Girolomoni G. Undertreatment in adult patients with moderate-to-severe atopic dermatitis and other inflammatory skin diseases. *J Eur Acad Dermatol Venereol* 34:2168–2169, 2020.
 54. Girolomoni G. Job: the prototypic dermatological patient Comments on a painting by Marcello Fogolino. *J Eur Acad Dermatol Venereol* 34:2175–2176, 2020.
 55. Tonin B, Catenaro R, Girolomoni G, Ghimenton C, Gisondi P. Pseudoepitheliomatous, keratotic and micaceous balanitis mimicking lichen sclerosus et atrophicus. *Dermatol Online* 2020;26:13030/qt7c33g14w
 56. Cork M, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, Girolomoni G, de Bruin-Weller M, Wollenberg A, Kataoko Y, Remitz A, Beissert S, Mastey V, Ardeleanu M, Chen Z, Gadkari A, Chao J. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. *J*

- Dermatolog Treat 31:606–614, 2020.
57. Gisondi P, Girolomoni G. Brodalumab in the treatment of chronic plaque psoriasis. *Expert Opin Biol Ther* 20:1175–1185, 2020.
 58. Gisondi P, Bellinato F, Girolomoni G. Topographic differential diagnosis of chronic plaque psoriasis: challenges and tricks. *J Clin Med* 9:3594, 2020.
 59. Tonin B, Geat D, Girolomoni G. An intriguing genital eruption in a traveler returning from Philippines. *Open J Clin Med Case Rep* 1649, 2020.
 60. Tonin B, Pizzolato P, Furci A, Girolomoni G. Cutaneus pili mirans. *Open J Clin Med Case Rep* 1535, 2020.
 61. Tonin B, Catenaro R, Gisondi P, Girolomoni G. Mycobacterium marinum infection acquired from a domestic aquarium. *Open J Clin Med Case Rep* 1659, 2020.
 62. Gisondi P, Bellinato F, Chiricozzi A, Girolomoni G. The risk of COVID-19 infection in patients with moderate to severe plaque psoriasis receiving systemic treatments. *Vaccines (Basel)* 8:E728, 2020.
 63. Chiricozzi A, Gisondi P, Bellinato F, Girolomoni G. Immune response to vaccination in psoriatic patients treated with systemic therapies. *Vaccines (Basel)* 8:E769, 2020.
 64. Gisondi P, Piaserico S, Bordin C, Alaibac M, Girolomoni G, Naldi L. Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. *J Eur Acad Dermatol Venereol* 34:2499–2504, 2020.
 65. Barker J, Girolomoni G, Egeberg A, Gonçalves J, Pieper B, Kang T. Anti-TNF biosimilars in psoriasis: From scientific evidence to real-world experience. *J Dermatolog Treat* 31:794–800, 2020.
 66. Dattola A, Balato A, Megna M, Gisondi P, Girolomoni G, De Simoni C, Caldarola G, Cama E, Piaserico S, Fagnoli MC, Fidanza R, Parodi A, Burlando M, Offidani A, Diotallevi F, Potenza C, Conti A, Chiricozzi A, Campione E, Bianchi L. Certolizumab for the treatment of psoriasis and psoriatic arthritis: A multicentre Italian study. *J Eur Acad Dermatol Venereol* 34:2939–2845, 2020.
 67. Tessari G, Maggiore U, Zaza G, Nguéfouet Momo RE, Nacchia F, Boschiero L, Sandrini S, Naldi L, Gotti E, Campise M, Messa P, Palmisano A, Capelli I, Minetti E, Rossini M, Girolomoni G. Mortality from cancer is not increased in kidney transplant recipients compared to the general population: a competing risk analysis. *J Nephrol* 33:1309–1319, 2020.
 68. Maurelli M, Colato C, Tessari G, Girolomoni G. Lichen planus pilaris effectively treated with brodalumab. *Dermatol Ther*, 33:e13967, 2020.
 69. Dal Bello G, Maurelli M, Schena D, Girolomoni G, Gisondi P. Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. *Dermatol Ther* 33:e13979, 2020.
 70. Gisondi P, Bellinato F, Bruni M, De Angelis G, Girolomoni G. Methotrexate versus secukinumab safety in psoriasis patients with metabolic syndrome. *Dermatol Ther* 33:e14281, 2020.
 71. Dal Bello G, Colato C, Rosina P, Girolomoni G. Nivolumab induced morphea. *G It Dermatol Venereol* 155:701–702, 2020.
 72. Gisondi P, Geat D, Lippi G, Montagnana M, Girolomoni G. Increased red blood cell distribution width in patients with plaque psoriasis. *J Med Biochem* 40:1–3, 2021.
 73. Gisondi P, Geat D, Girolomoni G. The place of apremilast in the real-life treatment of patients with plaque psoriasis. *J Eur Acad Dermatol Venereol* 35:13, 2021.
 74. Girolomoni G, Luger T, Nosbaum A, Gruben D, Romero W, Llamado LJ, DiBonaventura M. The economic and psychosocial comorbidity burden among adults with moderate-to severe atopic dermatitis in Europe. *Dermatol Ther (Heidelb)* 11:117–130, 2021.
 75. Gisondi P, Talamonti M, Chiricozzi A, Piaserico S, Amerio P, Balato A, Bardazzi F, Calzavara Pinton P, Campanati A, Cattaneo A, Dapavo P, De Simone C, Dini V, Fagnoli M C, Flori M L, Galluzzo M, Guarneri C, Lasagni C, Lo Schiavo A, Loconsole F, Malagoli P, Malara G, Mercuri S R, Musumeci M L, Naldi L, Papini M, Parodi A, Potenza C, Prignano F, Rongioletti F, Stingeni L, Tiberio R, Venturini M, Bianchi L, Costanzo A, Cusano F, Girolomoni G, Offidani AM, Peris K. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. *Dermatol Ther (Heidelb)* 11:235–252, 2021.
 76. Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G, Offidani A, Ferrucci SM, Amoroso GF, Rossi M, Stingeni L, Malara G, Grieco T, Foti C, Gattoni M, Loi C, Iannone M, Talamonti M, Stinco G, Rongioletti F, Pigatto PD, Cristaudo A, Nettis E, Corazza M, Guarneri F, Amerio P, Esposito M, Belloni Fortina A, Potenza C, Fabbrocini G. Dupilumab therapy of atopic dermatitis of the elderly: a multi-centre, real-life study. *J Eur Acad Dermatol Venereol* 35:958–964, 2021.
 77. Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Itch as a distinctive feature of type 2 immunity mediated diseases. *Vaccines (Basel)* 9:333, 2021.
 78. Esposito M, Giunta A, Gisondi P, Tambone S, Rovaris M, Manfreda V, Pirro F, Pellegrini C, Fagnoli MC, Bianchi L, Peris K, Girolomoni G. Satisfaction and attitudes toward systemic treatments for psoriasis: a cross-sectional study. *Dermatol Ther* e14949, 2021.
 79. Girolomoni G, de Bruin-Weller M, Aoki V, Kabashima K, Deleuran M, Puig L, Bansal A, Rossi AB. Nomenclature and

clinical phenotypes of atopic dermatitis. *Ther Adv Chronic Dis* 12:1–20, 2021.

80. Pezzolo E, Mutlu U, Vernooij MK, Dowlatshahi EA, Gisondi P, Girolomoni G, Nijsten T, Ikram A, Wakkee M. The association of psoriasis with cognition, brain imaging markers and risk of dementia: the Rotterdam study. *J Am Acad Dermatol* 00:000–000, 2021.
81. Gisondi P, Girolomoni G. The multifaceted association between psoriasis and obesity. *Br J Dermatol* 00:000–000, 2021.
82. Maurelli M, Colato C, Girolomoni G. Lymphoplasmocytic plaque of children: successful treatment with imiquimod. *G It Derma Venereol* 00:000–000, 2021.
83. Chiricozzi A, Gisondi P, Girolomoni G. The pharmacotherapy of chronic plaque psoriasis in obese patients. *Expert Opin Pharmacother* 00:000–000, 2021.
84. Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Sirna R, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavò SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Savi E, Stingeni L, Romano A, Argenziano G. Real-life experience on efficacy and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. *J Dermatolog Treat* 00:000–000, 2020.
85. Virga C, Maurelli M, Colato C, Girolomoni G. Idiopathic lichenoid and granulomatous dermatitis. *G It Dermatol Venereol* 00:000–000, 2021.
86. Mercurio L, Lulli D, Mascia F, Dellambra E, Scarponi C, Morelli M, Valente C, Carbone M, Pallotta S, Girolomoni G, Albanesi C, Pastore S, Madonna S. Intracellular Insulin-like Growth Factor Binding Protein 2 (IGFBP2) contributes to senescence of keratinocytes in psoriasis by stabilizing the cytoplasmic levels of p21. *Aging* 00:000–000, 2020.
87. Bellinato F, Maurelli M, Schena D, Gisondi P, Girolomoni G. Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. *G It Dermatol Venereol* 00:000–000, 2020.
88. Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Peccianti C, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavò SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Stingeni L, Caruso C, Argenziano G. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. *J Dermatolog Treat* 00:000–000, 2021.
89. Gisondi P, Geat D, Mattiucci A, Lombardo F, Santo A, Girolomoni G. Prevalence of adverse cutaneous reactions to epidermal growth factor receptor inhibitors in patients with non-small cell lung cancer. *Dermatology* 00:000–000, 2021.
90. Geat D, Tonin B, Colato C, Girolomoni G. A case of porokeratosis with predominant follicular involvement. *G Ital Dermatol Venereol* 00:000–000, 2021.
91. Cassano N, Genovese G, Asero R, Crimi N, Cristaudo A, Dapavo P, De Pità O, Ferrucci F, Fierro MT, Foti C, Girolomoni G, Nettis E, Offidani A, Patrizi A, Pepe P, Pigatto P, Stingeni L, Marzano AV, Vena GA. Chronic spontaneous urticaria in clinical practice: A pilot survey about attitudes and perceptions on assessment, diagnostic work-up and dietary management. *G Ital Dermatol Venereol* 00:000–000, 2021.
92. Cassano N, Genovese G, Asero R, Crimi N, Cristaudo A, Dapavo P, De Pità O, Ferrucci F, Fierro MT, Foti C, Girolomoni G, Nettis E, Offidani A, Patrizi A, Pepe P, Pigatto P, Stingeni L, Marzano AV, Vena GA. Therapeutic management of chronic spontaneous urticaria in clinical practice: Results from a pilot survey. *G Ital Dermatol Venereol* 00:000–000, 2021.
93. Gisondi P, Geat D, Mattiucci A, Lombardo F, Santo A, Girolomoni G. Prevalence of adverse cutaneous reactions to epidermal growth factor receptor inhibitors in patients with non-small cell lung cancer. *Dermatology* 00:000–000, 2021.
94. Dal Bello G, Colato C, Girolomoni G. Exfoliative cheilitis as a manifestation of factitial cheilitis in a young man. *G Ital Dermatol Venereol* 00:000–000, 2021.
95. HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. Morelli M, Galluzzo M, Madonna S, Scarponi C, Scaglione GL, Galluccio T, Andreani M, Pallotta S, Girolomoni G, Bianchi L, Talamonti M, Albanesi C. *Expert Opin Biol Ther* 00:000–000, 2021.
96. Gisondi P, Piaserico S, Bordin C, Tozzi F, Alaibac M, Girolomoni G, Naldi L. Hydroxychloroquine safety: cutaneous and extracutaneous adverse events. *Clin Exp Rheumatol* 00:000–000, 2021.
97. Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Clinical profile and co-infections of urethritis in males. *G Ital Dermatol Venereol* 00:000–000, 2021.

98. Geat D, Giovannini M, Barlocco EG, Pertile R, Farina S, Pace M, Fillipeschi C, Girolomoni G, Cristofolini M, Baldo E. Characteristics associated with clinical response to Comano thermal spring water balneotherapy in pediatric patients with atopic dermatitis. *It J Pediatrics* 00:000–000, 2021.
99. Chiricozzi A, Talamonti M, De Simone C, Galluzzo M, Gori N, Fabbrocini G, Marzano AV, Girolomoni G, Offidani AM, Rossi MT, Bianchi L, Cristaudo A, Fierro F, Stingeni L, Pellacani G, Argenziano G, Patrizi A, Pigatto P, Romanelli M, Savoia P, Rubegni P, Foti C, Milanese N, Belloni Fortin A, Bongiorno M, Grieco T, Di Nuzzo S, Fargnoli MC, Carugno A, Motolese M, Rongioletti F, Amerio P, Balestri R, Potenza C, Micali G, Patruno C, Zalaudek I, Lombardo M, Feliciani C, Guarneri F, Peris K. Management of the patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry. *Allergy* 00:000–000, 2021.
100. de Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, Hercogová J, Hong CH, Katoh N, Pink AE, Richard MA, Shumack S, Silvestre JF, Weidinger S. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. *Acta Derm Venereol* 00:000–000, 2021.
101. Geat D, Giovannini M, Barlocco EG, Pertile R, Pace M, Mori F, Novembre E, Girolomoni G, Cristofolini M, Baldo E. Assessing patients' characteristics and treatment patterns among children with atopic dermatitis. *It J Pediatrics* 00:000–000, 2021.
102. Piaserico S, Gisondi P, Cazzaniga S, Girolomoni G, Calzavara-Pinton PG, Naldi L. Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy? *J Eur Acad Dermatol Venereol* 00:000–000, 2021.
103. Dal Bello G, Schena D, Colato C, Girolomoni G. Nodules of the thigh after brown recuse spider venom bite. *Acta Derm Venereol. A quiz.* 00:000–000, 2021.
104. Bellinato F, Gisondi P, Maurelli M, Girolomoni G. IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review. *Dermatol Ther* 00:000–000, 2021.
105. Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L, Peris K, Ortoncelli M, Offidani A, Amoroso GF, Talamonti M, Girolomoni G, Grieco T, Iannone M, Nettis E, Foti C, Rongioletti F, Corazza M, Veneri MD, Napolitano M; Dupilumab for Atopic Dermatitis of the Elderly (DADE) Study Group. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicentre, real-life, observational study. *Am J Clin Dermatol* 00:000–000, 2021.
106. Furci A, Del Giglio M, Bellinato F, Colato C, Girolomoni G. Coexistence of scleromyxedema and Sneddon syndrome. *JAAD Case Rep* 00:000–000, 2021.
107. Maurelli M, Gisondi P, Colato C, Girolomoni G. Annually recurring erythema annulare centrifugum: a new case series with review of the literature. *Case Rep Dermatol* 00:000–000, 2021.
108. Moar A, Azzolini A, Tessari G, Schena D, Girolomoni G. Non-bullous pemphigoid: a single center retrospective study on disease characteristics. *Dermatology* 00:000–000, 2021.
109. Bellinato F, Maurelli M, Colato C, Gisondi P, Girolomoni G. Alopecic and aseptic nodules of the scalp: a new case with review of the literature. *Clin Case Rep* 00:000–000, 2021.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e del regolamento (UE) 2016/679 (GDPR). Si attesta inoltre la consapevolezza del rispetto alla responsabilità connesse a dichiarazioni mendaci (PDPR 445/2000 art 76).